SCHEMBL29317982

SCHEMBL29317982

COc1cc2nccc(Oc3cc(OC4CCOC4)cc(OC4CCOC4)c3)c2cc1C(N)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 11/20 0.55
KDR P35968 9/20 0.55
AURKB Q96GD4 5/20 0.55
PDGFRB P09619 2/20 0.55
KIT P10721 2/20 0.55
FGFR1 P11362 2/20 0.55
PDGFRA P16234 2/20 0.55
FLT1 P17948 2/20 0.55
FLT4 P35916 2/20 0.55
ABL1 P00519 2/20 0.55
RIPK2 O43353 1/20 0.55
ERN1 O75460 1/20 0.55
STK10 O94804 1/20 0.55
MAP3K6 O95382 1/20 0.55
ESR1 P03372 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
BCR P11274 1/20 0.55
NQO2 P16083 1/20 0.55
TBXA2R P21731 1/20 0.55
FGFR2 P21802 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050433 1.00 RET (0.55) RETKDRAURKBPDGFRBKIT
SCHEMBL30051302 0.98 RET (0.53) RETKDRAURKBPDGFRBKIT
SCHEMBL29186521 0.98 RET (0.53) RETKDRAURKBPDGFRBKIT
SCHEMBL29186528 0.98 RET (0.53) RETKDRAURKBPDGFRBKIT
SCHEMBL29186525 0.98 RET (0.53) RETKDRAURKBPDGFRBKIT
SCHEMBL29186560 0.84 DDR2 (0.46) PDE4ADDR2METIRAK4AXL
SCHEMBL29186557 0.84 DDR2 (0.46) PDE4ADDR2METIRAK4AXL
SCHEMBL30050496 0.84 DDR2 (0.46) PDE4ADDR2METIRAK4AXL
SCHEMBL29186540 0.84 IRAK4 (0.61) RETKDRAURKBPDGFRBKIT
SCHEMBL29186593 0.82 KDR (0.69) RETKDRAURKBPDGFRBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, CPT1A, OAT RET 4188/4885KDR 4885/4885AURKB 3997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.